Medicinal Products Prices

Dáil Éireann Debate, Tuesday - 20 June 2017

Tuesday, 20 June 2017

Ceisteanna (1015)

Stephen Donnelly

Ceist:

1015. Deputy Stephen S. Donnelly asked the Minister for Health the pharmaceutical products used by the HSE exclusively available from UK manufacturers; the annual cost of these products; the risks to ongoing availability in the case of no agreement being reached in Brexit negotiations; if contingency planning is in place for these products; the expected timeline for accreditation of these products in this scenario; and if he will make a statement on the matter. [26556/17]

Freagraí scríofa

Minister for Health

I have asked the HSE to reply directly to the Deputy on the issues raised that relate to the agency. Please advise my private office if you do not receive a reply within ten working days.

The medicines regulator, the Health Products Regulatory Authority (HPRA), is currently working to identify the key risks to continued availability of medicines under different Brexit scenarios. In parallel with this work, the HPRA is examining the feasibility of a number of risk mitigation measures to avoid delays in medicines authorisation and to protect the availability of medicines on the Irish market.